Swartling Carl, Naver Hans, Pihl-Lundin Inger, Hagforsen Eva, Vahlquist Anders
Department of Medical Sciences, Dermato-Venereology, Uppsala University, Uppsala, Sweden.
J Am Acad Dermatol. 2004 Nov;51(5):739-45. doi: 10.1016/j.jaad.2004.07.030.
Intradermal botulinum toxin (Btx) produces long-lasting relief of focal hyperhidrosis, but its mechanism of action is poorly understood.
To study the effect of Btx A on the size and innervation of sweat glands in patients with palmar hyperhidrosis.
Palmar skin biopsy was performed in 26 hyperhidrotic patients before scheduled Btx treatment and in 11 controls. Twelve of the patients also underwent biopsy 1 to 6 months after the Btx injections. Sweat gland morphology was investigated by light microscopy; the cross-sectional area of the secretory tubule and its lumen was measured by image analysis. Immunofluorescence (IF) with antibodies to the neural markers protein gene product 9.5 (PGP 9.5) and growth-associated protein 43 (GAP 43), and to vasoactive intestinal peptide (VIP) and calcitonin gene-related peptide (CGRP), was used to analyze the periglandular innervation.
The gross morphology of the sweat glands was similar in patients and controls, with no significant differences in tubular and luminal areas between the groups. After Btx treatment, the tubular dimensions remained unchanged, but the lumen tended to be smaller ( P = .07). Around the glands, increased GAP 43 staining indicating sprouting was seen within 3 months after Btx treatment ( P = .016); whereas the PGP 9.5 staining was decreased in most specimens ( P = .09) indicating lack of functional nerve growth. No change in VIP or CGRP immunoreactivity was observed.
The sweat glands appear structurally normal in hyperhidrotic patients before Btx therapy, whereas after therapy the luminal area of the gland is frequently diminished. The IF data GAP 43/PGP 9.5 suggest that Btx therapy induces long-standing functional denervation of the sweat glands, which might explain its anti-transpiratory efficacy.
皮内注射肉毒杆菌毒素(Btx)可长期缓解局限性多汗症,但其作用机制尚不清楚。
研究A型肉毒杆菌毒素(Btx A)对掌部多汗症患者汗腺大小及神经支配的影响。
对26例多汗症患者在预定的Btx治疗前及11例对照者进行掌部皮肤活检。其中12例患者在Btx注射后1至6个月也接受了活检。通过光学显微镜研究汗腺形态;通过图像分析测量分泌小管及其管腔的横截面积。使用针对神经标志物蛋白基因产物9.5(PGP 9.5)、生长相关蛋白43(GAP 43)、血管活性肠肽(VIP)和降钙素基因相关肽(CGRP)的抗体进行免疫荧光(IF)分析,以研究腺周神经支配情况。
患者和对照者的汗腺大体形态相似,两组之间小管和管腔面积无显著差异。Btx治疗后,小管尺寸保持不变,但管腔有变小趋势(P = 0.07)。在腺体周围,Btx治疗后3个月内可见GAP 43染色增加,表明有新芽生长(P = 0.016);而大多数标本中PGP 9.5染色减少(P = 0.09),表明缺乏功能性神经生长。未观察到VIP或CGRP免疫反应性的变化。
在Btx治疗前,多汗症患者的汗腺结构似乎正常,而治疗后腺体的管腔面积经常减小。IF数据GAP 43/PGP 9.5表明,Btx治疗可导致汗腺长期功能性去神经支配,这可能解释了其止汗效果。